TAHOC: The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

Sponsor

Central Hospital, Nancy, France (Other)

Overall Status

Completed

CT.gov ID

NCT05845736

Collaborator

(none)

353

Enrollment

Location

11.3

Actual Duration (Months)

31.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.

Condition or Disease	Intervention/Treatment	Phase
Neurocognitive Disorders Dementia Hypertension Aged, 80 and Over	Drug: Antihypertensive Agents

Study Design

Study Type:

Observational

Actual Enrollment :

353 participants

Observational Model:

Case-Control

Time Perspective:

Retrospective

Official Title:

The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study

Actual Study Start Date :

Jan 1, 2022

Actual Primary Completion Date :

Jan 1, 2022

Actual Study Completion Date :

Dec 12, 2022

Arms and Interventions

Arm	Intervention/Treatment
control group absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive	Drug: Antihypertensive Agents number of hypertensive drugs
mild neurocognitive disorder MMSE from 21 to 26 inclusive	Drug: Antihypertensive Agents number of hypertensive drugs
moderate neurocognitive disorder MMSE from 11 to 20 inclusive	Drug: Antihypertensive Agents number of hypertensive drugs
severe neurocognitive disorder MMSE less than or equal to 10	Drug: Antihypertensive Agents number of hypertensive drugs

Outcome Measures

Primary Outcome Measures

number of antihypertensive agents [during inclusion]
among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker

Secondary Outcome Measures

class of antihypertensive medications [during inclusion]
among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker
systolic and diastolic blood pressure [during inclusion]
blood pressure measured with upper arm cuffs
orthostatic hypotension [during inclusion]
a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing